Zogenix, Valeant in Migranal Co-Promotion Pact

Zogenix, Inc. has entered an exclusive co-promotion agreement for Migranal (dihydroergotamine mesylate, USP) Nasal Spray in the U.S. Zogenix’s will begin selling Migranal to its customer base of prescribers in late July 2013. The initial term of the agreement will be through December 31, 2015, and can be extended. Valeant will record all product revenues and Zogenix will be compensated in the form of a quarterly service fee based on a percentage of sales. Migranal is indicated for the treatment of migraine headaches with or without aura.
 
Roger L. Hawley, chief executive officer of Zogenix, said, “We are pleased to enter a co-promotion agreement with Valeant for Migranal Nasal Spray. We view Migranal as complementary to SUMAVEL DosePro and supportive of the migraine treatment guidelines, which encourage the use of a toolbox of treatment options to address the variety in migraine attacks. We believe this agreement fits well with our vision to be the leading specialty migraine company and help drive our commercial operations towards profitability.”